From: Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
Grade ≥ 3 adverse events
Afatinib (%)
Pemetrexed-cisplatin (%)
Neutropenia
0.4
18.0
Fatigue
1.3
12.6
Anaemia
6.3
Nausea
0.9
3.6
Diarrhoea
14.4
0.0
Rash
16.2
Vomiting
3.1
2.7